Xilio Therapeutics (XLO) Cash from Operations Growth (1y) (2021 - 2026)
Xilio Therapeutics (XLO) Cash from Operations Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 4.87% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -28.96% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 42.76% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 75.58% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 151.70% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 172.77% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 56.79% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 100.14% |
| 10 | Xilio Therapeutics | 178.33 Mn | 42.29 Mn | - | -29.60% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -29.60% |
| Mar 31, 2026 | -177.10% |
| Dec 31, 2025 | 85.89% |
| Sep 30, 2025 | -27.96% |
| Jun 30, 2025 | -172.56% |
| Mar 31, 2025 | 375.93% |
| Dec 31, 2024 | -5.44% |
| Sep 30, 2024 | -2.27% |
| Jun 30, 2024 | 220.39% |
| Mar 31, 2024 | 58.41% |
| Dec 31, 2023 | 26.32% |
| Sep 30, 2023 | 32.85% |
| Jun 30, 2023 | 1.09% |
| Mar 31, 2023 | -21.19% |
| Dec 31, 2022 | -6.18% |
| Sep 30, 2022 | 3.91% |
| Jun 30, 2022 | 16.79% |
| Mar 31, 2022 | 8.35% |
| Dec 31, 2021 | -35.08% |